Plaque-type Psoriasis Clinical Trial
Official title:
A Randomized, Double-blind, Double Dummy, Multicenter Study to Assess the Safety, Tolerability and Long-term Efficacy of Intravenous (10mg/kg) and Subcutaneous (300mg) Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Who Are Partial Responders to Secukinumab
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01936688 -
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
|
Phase 3 | |
Completed |
NCT00763503 -
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
|
Phase 2 | |
Completed |
NCT00773734 -
Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
|
Phase 2 | |
Completed |
NCT01636687 -
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
|
Phase 3 | |
Completed |
NCT01258088 -
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis
|
Phase 1 | |
Completed |
NCT01132612 -
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT00852761 -
A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
|
Phase 4 | |
Completed |
NCT00625326 -
Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis
|
Phase 2 | |
Completed |
NCT00521339 -
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT01876875 -
n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis
|
Phase 4 |